Literature DB >> 15860511

Combination treatment strategies in early rheumatoid arthritis.

E Suresh1, C M Lambert.   

Abstract

Combinations of disease modifying antirheumatic drugs (DMARDs) are increasingly being used in patients with early rheumatoid arthritis (RA) when long term results with sequential DMARD monotherapy are disappointing. Combination DMARD therapy may be more effective than monotherapy, and has no additional short term adverse events. The evidence for using combination DMARD therapy is still weak, however, and further trials are needed.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15860511      PMCID： PMC1755668          DOI： 10.1136/ard.2004.032219

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  53 in total

1.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

2.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

3.  Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope.

Authors:  M Green; H Marzo-Ortega; D McGonagle; R Wakefield; S Proudman; P Conaghan; J Gooi; P Emery
Journal:  Arthritis Rheum       Date:  1999-10

4.  HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments.

Authors:  J R O'Dell; B S Nepom; C Haire; V H Gersuk; L Gaur; G F Moore; W Drymalski; W Palmer; P J Eckhoff; L W Klassen; S Wees; G Thiele; G T Nepom
Journal:  Ann Rheum Dis       Date:  1998-04       Impact factor: 19.103

5.  Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.

Authors:  C Egsmose; B Lund; G Borg; H Pettersson; E Berg; U Brodin; L Trang
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

6.  Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.

Authors:  J R O'Dell; C Haire; N Erikson; W Drymalski; W Palmer; P Maloley; L W Klassen; S Wees; G F Moore
Journal:  J Rheumatol Suppl       Date:  1996-03

Review 7.  Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis.

Authors:  D E Furst
Journal:  J Rheumatol Suppl       Date:  1996-03

8.  Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study.

Authors:  R Munro; R Hampson; A McEntegart; E A Thomson; R Madhok; H Capell
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

9.  Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression.

Authors:  A A Stenger; M A Van Leeuwen; P M Houtman; G A Bruyn; F Speerstra; B C Barendsen; E Velthuysen; M H van Rijswijk
Journal:  Br J Rheumatol       Date:  1998-11

10.  Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group.

Authors:  P Hickling; R K Jacoby; J R Kirwan
Journal:  Br J Rheumatol       Date:  1998-09
View more
  1 in total

Review 1.  Phenolic Compounds Impact on Rheumatoid Arthritis, Inflammatory Bowel Disease and Microbiota Modulation.

Authors:  Rosa Direito; João Rocha; Bruno Sepodes; Maria Eduardo-Figueira
Journal:  Pharmaceutics       Date:  2021-01-22       Impact factor: 6.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.